ArticleFrontiers in immunology2026
Longitudinal plasma proteomics identifies diagnostic and response-associated inflammatory and immune biomarkers in psoriasis following secukinumab therapy.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- CEACAM5 drives psoriatic inflammation by regulating CD8Biochemistry and biophysics reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Psoriasis (PSO) is a chronic immune-mediated inflammatory skin disease characterized by keratinocyte hyperproliferation and dysregulated activation of the IL-23/IL-17 axis, leading to persistent cutaneous inflammation and substantial disease burden. Comprehensive profiling of circulating inflammatory proteins provides important insights into the systemic immune alterations associated with PSO and its treatment. However, the longitudinal plasma proteomic changes induced by IL-17A blockade remain incompletely characterized. Methods: We quantified the expression levels of 92 inflammation-related proteins in plasma samples from 10 patients with moderate-to-severe PSO before and during secukinumab therapy, as well as from 10 healthy controls (NC), using the Olink Target 96 Inflammation panel. Key differentially expressed proteins were further validated by enzyme-linked immunosorbent assay (ELISA). Longitudinal patterns were assessed using Mfuzz clustering, and functional enrichment analyses were performed to explore the underlying biological pathways. Results: Baseline plasma proteomic profiles clearly discriminated PSO patients from healthy individuals, with CXCL1, CXCL5, CCL20, and HGF exhibiting the most pronounced alterations and the highest diagnostic performance. Longitudinal analysis revealed a coordinated reduction of multiple inflammatory mediators following IL-17A inhibition, including CCL20, IL-17C, IL-6, and OSM. Mfuzz analysis identified two dominant temporal expression patterns characterized by a progressive decrease in inflammatory and immune-related proteins over the course of secukinumab treatment. Notably, baseline circulating IL-17C levels were significantly positively correlated with disease severity, suggesting its potential as a biomarker of therapeutic response. Functional enrichment analysis indicated that differentially expressed proteins (DEPs) were mainly involved in cytokine-cytokine receptor interaction and IL-17-related signaling pathways. Discussion: To our knowledge, this is the first study to characterize the longitudinal plasma proteomic landscape of PSO patients treated with secukinumab using the Olink platform. This work provides molecular evidence for the systemic immunomodulatory effects of IL-17A blockade and highlights candidate circulating biomarkers for disease monitoring and treatment response in PSO. Given the small sample size, these results should be validated in larger, independent cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.